Literature DB >> 26628839

HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection.

Sundeep K Goyal1, Ashok K Jain1, Vinod K Dixit1, Suneet K Shukla1, Mohan Kumar2, Jayant Ghosh1, Arttrika Ranjan1, Neha Gupta1, Manish Tripathi1.   

Abstract

BACKGROUND AND AIMS: Preliminary data suggests lower serum hepatitis B surface antigen level is associated with more severe liver fibrosis in HBeAg positive patients. We evaluated the association of HBsAg level with biochemical, virological, and histological features in asymptomatic patients with chronic HBV infection.
METHODS: HBsAg levels were measured at baseline in 481 asymptomatic, treatment naive patients with chronic HBV infection. Subjects were followed-up prospectively (median, 12; range, 8-36 months). Phases of HBV infection were defined after regular monitoring of HBV-DNA and transaminases. Liver histology was scored using the METAVIR system.
RESULTS: HBeAg positive (n, 126) patients were significantly younger than HBeAg negative (n, 355), median age 26 vs 30 years; P < 0.01. HBV genotype could be determined in 350 patients, 240 (68.57%) had genotype D and 100 (28.57%) had genotype A. HBsAg level had modest correlation with serum HBV DNA(r = 0.6 vs 0.4 in eAg positive &amp; negative respectively). HBeAg + ve patients with fibrosis score ≥ F2 showed significantly lower median serum HBsAg levels and serum HBV DNA levels compared with patients with F0-F1 score (median, range; 4.51, 2.99-6.10 vs 5.06, 4.13-5.89, P < 0.01) and (8.39, 3.85-10.60, P < 0.01) respectively. Significant inverse correlation of HBsAg level was found with liver fibrosis in eAg positive group (r = -0.76; P < 0.001). HBsAg level cut off value 4.7 log10 IU/ml predicted moderate to advance fibrosis (F ≥ 2) with 92% sensitivity, 85% specificity &amp; 91% negative predictive value.
CONCLUSION: Lower HBsAg level might reflect the status of advanced liver fibrosis in HBeAg positive chronic hepatitis B subjects.

Entities:  

Keywords:  ALT, alanine aminotransferase; HBV, hepatitis B virus; HBsAg quantification; HCC, hepatocellular carcinoma; ROC, receiver operating characteristics; chronic HBV infection; chronic hepatitis B; hepatic fibrosis; liver fibrosis

Year:  2015        PMID: 26628839      PMCID: PMC4632094          DOI: 10.1016/j.jceh.2015.04.008

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  31 in total

Review 1.  Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment.

Authors:  Jordan J Feld; E Jenny Heathcote
Journal:  Semin Liver Dis       Date:  2006-05       Impact factor: 6.115

2.  Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.

Authors:  Tin Nguyen; Alexander J V Thompson; Scott Bowden; Catherine Croagh; Sally Bell; Paul V Desmond; Miriam Levy; Stephen A Locarnini
Journal:  J Hepatol       Date:  2010-02-16       Impact factor: 25.083

3.  Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients.

Authors:  Michelle Martinot-Peignoux; Roberto Carvalho-Filho; Martine Lapalus; Ana Carolina Ferreira Netto-Cardoso; Olivier Lada; Richard Batrla; Friedemann Krause; Tarik Asselah; Patrick Marcellin
Journal:  J Hepatol       Date:  2013-01-28       Impact factor: 25.083

4.  Role of proinflammatory cytokines (interferon gamma) and anti-inflammatory cytokine (interleukin-10) gene polymorphisms in chronic hepatitis B infection: an Indian scenario.

Authors:  Manjita Srivastava; Arttrika Ranjan; Jitendra K Choudhary; Manish K Tripathi; Smita Verma; Vinod K Dixit; Gopal Nath; Ashok K Jain
Journal:  J Interferon Cytokine Res       Date:  2014-01-21       Impact factor: 2.607

5.  Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

Authors:  Jerzy Jaroszewicz; Beatriz Calle Serrano; Karsten Wursthorn; Katja Deterding; Jerome Schlue; Regina Raupach; Robert Flisiak; C-Thomas Bock; Michael P Manns; Heiner Wedemeyer; Markus Cornberg
Journal:  J Hepatol       Date:  2010-02-13       Impact factor: 25.083

Review 6.  Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review.

Authors:  George V Papatheodoridis; Spilios Manolakopoulos; Yun-Fan Liaw; Anna Lok
Journal:  J Hepatol       Date:  2012-03-23       Impact factor: 25.083

7.  Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.

Authors:  Faisal M Sanai; Mohammed A Babatin; Khalid I Bzeizi; Fahad Alsohaibani; Waleed Al-Hamoudi; Khaled O Alsaad; Hadeel Al Mana; Fayaz A Handoo; Hamad Al-Ashgar; Hamdan Alghamdi; Abeer Ibrahim; Abdulrahman Aljumah; Abduljaleel Alalwan; Ibrahim H Altraif; Hussa Al-Hussaini; Robert P Myers; Ayman A Abdo
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-28       Impact factor: 11.382

8.  Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Authors:  Rami Moucari; Vincent Mackiewicz; Olivier Lada; Marie-Pierre Ripault; Corinne Castelnau; Michelle Martinot-Peignoux; Agnes Dauvergne; Tarik Asselah; Nathalie Boyer; Pierre Bedossa; Dominique Valla; Michel Vidaud; Marie-Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

9.  The use of transient elastography in the management of chronic hepatitis B.

Authors:  James Fung; Ching-Lung Lai; Wai-Kay Seto; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2011-06-22       Impact factor: 6.047

10.  A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B.

Authors:  Wai-Kay Seto; Ching-Lung Lai; Philip P C Ip; James Fung; Danny Ka-Ho Wong; John Chi-Hang Yuen; Ivan Fan-Ngai Hung; Man-Fung Yuen
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

View more
  2 in total

1.  A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels.

Authors:  Yanping Chen; Yanping Li; Na Li; Xiude Fan; Chunyan Li; Pingping Zhang; Qunying Han; Zhengwen Liu
Journal:  Dis Markers       Date:  2018-10-14       Impact factor: 3.434

2.  Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection.

Authors:  Zhan-Qing Zhang; Bi-Sheng Shi; Wei Lu; Dan-Ping Liu; Dan Huang; Yan-Ling Feng
Journal:  Can J Infect Dis Med Microbiol       Date:  2019-12-25       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.